stavudine (zerit) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.   NCATS

  • SMILES: CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
  • Mol. Mass: 224.2133
  • ALogP: -0.71
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No
1-(2,3-dideoxy-beta-d-glycero-pent-2-enofuranosyl)thymine | 2',3'-didehydro-3'-deoxythimidine | 3'-deoxy-2'-thymidinene | bmy-27857 | d4t | estavudina | sanilvudine | staduvine | stavudin | stavudine | stavudine (d4t) | stavudinum | stv | triomune | zerit | zerit, stavudine | zerit xr


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue